//
Precede Consortium Incorporated is a private corporation based in RED HOOK, NY. The foundation received its IRS ruling in 2022. It holds total assets of $205K. Annual income is reported at $1. Building a population-based familial cohort of individuals who are at high-risk of developing pancreatic cancer. In partnership Arbor Research, Precede over the next 5 years will be forming a consortium of cancer centers from around the world to develop and maintain a common database on the ArborLink platform, including clinical and family history information, as well as cataloguing and tracking of biological samples and imaging data. The scientific goal of the consortium includes (1) improving risk modeling for pancreatic cancer, based on the genetic and environmental risk factors, (2) developing a validation cohort for an early detection test for pancreatic cancer, (3) testing the concept that screening in this population will saves lives, (4) performing clinical trials using the early detection test. Contributions to this foundation are tax-deductible.
Building a population-based familial cohort of individuals who are at high-risk of developing pancreatic cancer. In partnership Arbor Research, Precede over the next 5 years will be forming a consortium of cancer centers from around the world to develop and maintain a common database on the ArborLink platform, including clinical and family history information, as well as cataloguing and tracking of biological samples and imaging data. The scientific goal of the consortium includes (1) improving risk modeling for pancreatic cancer, based on the genetic and environmental risk factors, (2) developing a validation cohort for an early detection test for pancreatic cancer, (3) testing the concept that screening in this population will saves lives, (4) performing clinical trials using the early detection test.
Expenses: $705K
Building a population-based familial cohort of individuals who are at high-risk of developing pancreatic cancer. In partnership Arbor Research, Precede over the next 5 years will be forming a consortium of cancer centers from around the world to develop and maintain a common database on the ArborLink platform, including clinical and family history information, as well as cataloguing and tracking of biological samples and imaging data. The scientific goal of the consortium includes (1) improving risk modeling for pancreatic cancer, based on the genetic and environmental risk factors, (2) developing a validation cohort for an early detection test for pancreatic cancer, (3) testing the concept that screening in this population will saves lives, (4) performing clinical trials using the early detection test.
Precede Consortium Incorporated typically selects its grantees rather than accepting unsolicited proposals.
Precede Consortium Incorporated is headquartered in RED HOOK, NY.
| Name | Title | Compensation | Benefits | Total |
|---|---|---|---|---|
| Diane Simeone Md | Committee Chair | $0 | $0 | $0 |
| Fay Kastrinos Md | P. Investigator | $0 | $0 | $0 |
| Aimee Lucas Md Ms | P. Investigator | $0 | $0 | $0 |
| George Zogopoulos Md Phd | P. Investigator | $0 | $0 | $0 |
| Randall Brand Md | P. Investigator | $0 | $0 | $0 |
Total Giving
$703K
Total Assets
$205K
Fair Market Value
$205K
Net Worth
$205K
Grants Paid
$0
Contributions
$0
Net Investment Income
$0
Distribution Amount
$0
| Rosie Sears Phd |
| P. Investigator |
| $0 |
| $0 |
| $0 |
| Sonia Kupfer Md | P. Investigator | $0 | $0 | $0 |
| John Graff Phd Ms | Program Dir. | $0 | $0 | $0 |
| Giovanni Parmigiani Phd | Program Dir. | $0 | $0 | $0 |
© 2026 Granted AI